Short Interest in enGene Holdings Inc. (NASDAQ:ENGNW) Expands By 400.0%

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 1,500 shares, a growth of 400.0% from the May 31st total of 300 shares. Based on an average daily volume of 7,600 shares, the short-interest ratio is currently 0.2 days.

enGene Stock Performance

NASDAQ ENGNW opened at $1.19 on Friday. The business has a fifty day moving average price of $2.82 and a two-hundred day moving average price of $2.76. enGene has a fifty-two week low of $0.39 and a fifty-two week high of $6.50.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.